Phio Pharma Shares Are Moving Higher On INTASYL Preclinical Data At ESMO Presentation

  • Phio Pharmaceuticals Corp PHIO has announced preclinical results from a new study of a self-delivering RNAi (INTASYL) therapeutic platform.
  • The data were presented at the European Society of Medical Oncology (ESMO) Congress 2021.
  • The study was performed to show the synergistic activity of co-targeting PD-1 and BRD4 with one INTASYL formulation (PH-3861) in a preclinical in vivo hepatocellular carcinoma (liver cancer) model. 
  • The results show that up to 83% of the animals treated with PH-3861 had a complete response at low doses.
  • The treatment induced a durable and specific systemic antitumor immune response without requiring further treatment.
  • Related Link: Phio Pharma's PH-762 Shows Encouraging Antitumor Efficacy In Preclinical Studies.
  • Price Action: PHIO stock is up 18.80% at $2.34 during the premarket session on the last check Thursday.
  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsESMO21Liver CancerPreclinical Phase
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!